Biosimilar Interleukins Market Report 2025 – Insights for Decision Makers and Market Strategists

Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts.

What is the forecasted revenue size of the biosimilar interleukins industry by 2029?
The biosimilar interleukins market size has grown exponentially in recent years. It will grow from $3.9 billion in 2024 to $5.41 billion in 2025 at a compound annual growth rate (CAGR) of 39.0%. The growth in the historic period can be attributed to the rising prevalence of autoimmune diseases, increasing awareness of biosimilar interleukins, growing government support for biosimilars, expansion of the biosimilar, and increasing patient demand for biosimilars.

The biosimilar interleukins market size is expected to see exponential growth in the next few years. It will grow to $20.79 billion in 2029 at a compound annual growth rate (CAGR) of 40.0%. The growth in the forecast period can be attributed to the growing patient population, increased access to healthcare, growing demand for personalized medicine, and growing demand for minimally invasive procedures. Major trends in the forecast period include advances in biosimilar technology, targeted immunotherapies, quality control and manufacturing, and global collaboration.

Download Your Free Sample PDF:
Comprehensive Report on Global Biosimilar Interleukins Market Size 2025 Sample

Which industry-specific innovations are acting as key drivers for the biosimilar interleukins market?
The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefits in regulating the cells, and in directing proliferation, activation, and migration of the cells. For instance, in February 2024, according to reports published by the National Institutes of Health (NIH), a US-based biomedical research agency, the estimated annual increases in the global incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively. Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market.

Which segment currently leads the biosimilar interleukins market in terms of revenue share?
The biosimilar interleukins market covered in this report is segmented –

1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment

View The Full Market Report:
Comprehensive Report on Global Biosimilar Interleukins Market Size 2025

What future trends will impact the direction of the biosimilar interleukins industry?
Major companies operating in the biosimilar interleukins market are innovating new products such as Tofidence (tocilizumab-bavi) to increase their profitability in the market. Tofidence is a monoclonal antibody that targets and attaches to interleukin-6 receptors, employed in the treatment of various inflammatory autoimmune disorders. For instance, in September 2023, Biogen, a US-based biotechnology company got approval from the FDA for Tofidence (tocilizumab-bavi) as the first biosimilar to reference Genentech's Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has received approval for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

Who are the top competitors in the global biosimilar interleukins market?
Major companies operating in the biosimilar interleukins market include Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.

What regional dynamics are shaping the future of the global biosimilar interleukins market?
The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

How Can Companies Use The Biosimilar Interleukins Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.

Purchase The Report And Get A Swift Delivery:
Comprehensive Report on Global Biosimilar Interleukins Market Size 2025

Need Customized Data On Biosimilar Interleukins Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.

Request Customized Data:
Comprehensive Report on Global Biosimilar Interleukins Market Size 2025 Customise

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info


Follow Us On:

LinkedIn: The Business Research Company | LinkedIn